By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish, with key concerns being potential EPS decline in 2026 driven by Medicaid redeterminations, Medicare Advantage star rating pressures, and rising medical loss ratios. The market may be underestimating these headwinds, and Carelon's growth may not offset these issues.
Risk: Medicaid redeterminations and Medicare Advantage star rating pressures leading to EPS decline in 2026
Opportunity: Carelon's potential to drive operating margin expansion and offset core declines
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Argus
•
May 14, 2026
Summary
Elevance is a health benefits company. It operates through two segments: Health Benefits and Carelon Services. The Health Benefits segment provides insurance to members to individuals, employer groups, Medicaid, Medicare Advantage, and the federal sector. Carelon is composed of Carelon Rx, which provides prescription management services, and Carelon Services. The services include medical benefit and behaviora
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade### Analyst Profile
David H. Toung
Senior Analyst: Medical Devices & Healthcare Services
David covers the Pharmaceutical, Medical Devices, and Healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase and Standard & Poor's, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, David was a private practice attorney in New Jersey, and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. David has a law degree from Rutgers University, where he was a member of the Law Review. He has a B.A. degree in Government from Cornell University. He has passed Level II of the Chartered Financial Analyst examination.
Four leading AI models discuss this article
"Elevance’s 2026 EPS decline reflects a critical transition point where the company must prove that its Carelon services can provide enough margin offset to compensate for deteriorating insurance segment fundamentals."
The report highlights a projected EPS decline for Elevance Health (ELV) in 2026, a significant red flag for a company historically valued on consistent earnings growth. Market sentiment is likely pricing in regulatory pressure on Medicare Advantage star ratings and rising medical loss ratios (MLR). However, the market may be underestimating the long-term margin expansion potential of the Carelon segment. If Carelon’s integrated pharmacy and behavioral health services can successfully lower total cost of care, ELV could offset insurance underwriting volatility. I am watching the 2026 guidance closely; if the EPS contraction is driven by one-time investments rather than structural membership loss, the current valuation could present a value trap or a tactical entry point.
The bearish case ignores that ELV’s scale allows it to absorb MLR volatility better than smaller peers, and the shift toward value-based care could lead to a structural re-rating of the stock if Carelon achieves sufficient operating leverage.
"Argus' EPS decline warning for 2026 underscores persistent medical cost pressures in ELV's Health Benefits segment that Carelon growth may not fully mitigate."
Argus' report flags a 2026 EPS decline for Elevance Health (ELV), a leading health insurer with Health Benefits (covering commercial, Medicaid, Medicare Advantage) and Carelon Services (Rx and behavioral health). Paywall limits details, but title implies margin squeezes from rising medical costs or utilization—common in Medicare Advantage amid CMS rate scrutiny. ELV trades at ~13x 2025 EPS (per recent data), vulnerable if trends persist; peers like UNH/CI face similar MLR (medical loss ratio) pressures. Second-order risk: regulatory changes post-election could exacerbate. Bullish offset might be Carelon's scale, but unproven at offsetting core declines. Stress-test: monitor MLR in upcoming quarters.
This 2026 projection may already bake in conservative assumptions on cost trends, which moderated in 2024; if CarelonRx gains share in pharmacy benefits, EPS could inflect positively sooner.
"This article contains no actionable data; without EPS guidance, magnitude of decline, or root cause, the headline is unfalsifiable and the recommendation undeserving of portfolio action."
The article headline promises substance—'EPS decline in 2026'—but delivers almost nothing. We get a business description and a bio; no actual numbers, no guidance context, no comparison to consensus estimates, no explanation of *why* EPS is declining. Is this a macro headwind (medical loss ratios rising)? A one-time charge? Carelon underperformance? Without that, the headline is noise. H trades ~$430; I need to know if this is a 5% miss or a 25% miss, and whether it's priced in. The article is functionally incomplete.
If Argus is flagging an EPS miss before the market has fully repriced it, even a vague warning can be valuable—and the analyst's healthcare pedigree (JPMorgan, S&P) suggests he's not publishing blind. The incompleteness might be intentional paywall bait, not incompetence.
"Carelon Services can deliver meaningful margin expansion and cash-flow growth that offsets the 2026 EPS decline."
Big picture: Argus flags a 2026 EPS decline for Elevance Health, signaling near-term headwinds. The bull case rests on three levers: Carelon Services driving operating margin expansion, Rx optimization improving pharmacoeconomic efficiency, and stronger cash flow from value-based contracts; plus potential upside from Medicare Advantage premium growth and stabilized membership. However, the article underplays execution risk in Carelon integration, potential pricing pressure and drug-cost reforms, and payer mix shifts (Medicaid vs. MA). (Speculative) If MA risk corridors tighten or MA enrollment slows, the near-term EPS downside could be larger than implied.
(Strongest counter) The near-term EPS decline could be structural and persistent if medical costs run hotter than expected or Carelon integration lags, eroding any margin benefits. If MA risk corridors tighten or premium growth stalls, the upside from Carelon may not materialize.
"The projected 2026 EPS decline is likely driven by Medicaid revenue normalization rather than just MLR volatility or Carelon execution."
Claude is right to call out the lack of data, but we are ignoring the elephant in the room: the Medicaid redetermination cycle. ELV’s exposure to Medicaid is massive. If the EPS decline in 2026 is driven by state-level contract repricing or churn as eligibility stabilizes, Carelon’s growth won't matter. We are debating margin expansion while the underlying revenue base for their core insurance segment faces a structural reset that the market is clearly underestimating.
"Medicaid churn is largely complete; 2026 EPS risk centers on MA stars and drug utilization, not state repricing."
Gemini fixates on Medicaid redeterminations, but those peaked in 2024 with enrollment stabilizing (ELV lost ~1M lives but premiums rose). By 2026, the EPS drop likely ties to Medicare Advantage star rating pressures (CMS scrutiny on upcoding) and MLR creep from GLP-1 utilization—unmentioned here. Carelon won't offset if MA membership erodes 2-3%. Check Q2 MLR vs. 86.5% guidance.
"The 2026 EPS decline likely reflects compounding pressures (Medicaid repricing + MA MLR creep), not a single cyclical headwind, making the current valuation vulnerable if either thesis proves larger than consensus assumes."
Grok and Gemini are talking past each other on timing. Medicaid redeterminations *did* peak in 2024, but ELV's 2026 guidance reflects forward assumptions—the question is whether state contract repricing (Gemini's thesis) or MA star-rating erosion (Grok's thesis) dominates the EPS miss. These aren't mutually exclusive; both could compress margins simultaneously. The real stress test: which headwind is *priced in* at 13x 2025 EPS? If neither is, downside widens.
"Carelon margin leverage could offset MA headwinds, but only if data shows it; otherwise 2026 EPS declines could be larger than implied."
Grok, I push back on timing. MA star rating and MLR pressure are real, but you treat 2026 as a one-way squeeze. The more relevant question is Carelon’s marginal leverage once scale stabilizes, which you don’t quantify. If Carelon hits operating leverage, the EPS hit from MA could be offset by margin expansion; if not, the stock truly derates. The dubious part is assuming a clean offset without data.
The panel consensus is bearish, with key concerns being potential EPS decline in 2026 driven by Medicaid redeterminations, Medicare Advantage star rating pressures, and rising medical loss ratios. The market may be underestimating these headwinds, and Carelon's growth may not offset these issues.
Carelon's potential to drive operating margin expansion and offset core declines
Medicaid redeterminations and Medicare Advantage star rating pressures leading to EPS decline in 2026